Compounds > canertinib
Page last updated: 2024-09-04

canertinib and nintedanib

canertinib has been researched along with nintedanib in 3 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(nintedanib)		Trials
(nintedanib)		Recent Studies (post-2010) (nintedanib)
124965846133801

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)nintedanib (IC50)
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.085
Tyrosine-protein kinase LckHomo sapiens (human)0.016
Tyrosine-protein kinase LynHomo sapiens (human)0.1483
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0133
Fibroblast growth factor receptor 1Homo sapiens (human)0.068
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.1093
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.017
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0395
Fibroblast growth factor receptor 2Homo sapiens (human)0.037
Fibroblast growth factor receptor 4Homo sapiens (human)0.61
Fibroblast growth factor receptor 3Homo sapiens (human)0.108
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.085
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0116
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)0.013
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.009
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.026
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.0026
Maternal embryonic leucine zipper kinaseHomo sapiens (human)0.043

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

3 other study(ies) available for canertinib and nintedanib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017